TESARO and Myriad Announce Companion Diagnostics

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TESARO and Myriad Announce Companion Diagnostics Collaboration

BARCELONA, Spain, Nov. 20, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO ) and Myriad Genetics (Nasdaq: MYGN ) today announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, TESARO will utilize Myriad's test to enrich the target population for potential responders to niraparib. Myriad will provide testing services and pursue necessary regulatory approvals in support of TESARO's development of niraparib.

The Companies also described new data demonstrating that Myriad's myChoice HRD™ score is predictive of niraparib sensitivity in patient-derived xenograft models of ovarian cancer. These results were presented today by Dr. Paul Haluska, Jr., M.D., Ph.D., Associate Professor of Oncology at the Mayo Clinic, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

"Myriad's myChoice HRD diagnostic test identifies the inherent biology of the tumor and differentiates tumors with homologous repair deficiencies from those without such deficiencies," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Niraparib sensitivity in patient-derived xenograft models is associated with HRD status as defined by the myChoice HRD test."

"We are excited to be expanding our collaboration with TESARO as we strongly believe new diagnostics such as myChoice HRD, combined with targeted therapies such as niraparib, have the potential to significantly improve patient care," said Jerry Lanchbury, Ph.D., Chief Scientific Officer at Myriad. "myChoice HRD utilizes three proprietary measures to assess the genomic scar associated with the loss of DNA repair and has been shown in multiple clinical studies to be the most comprehensive predictor of tumor response to DNA damaging agents such as niraparib."

Summary of Xenograft Study Results

Patient-derived xenografts were created from more than 100 high grade serious ovarian cancer tumor samples. HRD testing was performed on each sample using myChoice HRD to define HRD status, detect BRCA 1 and 2 mutations and identify hypermethylation of BRCA genes. Approximately half of these models were HRD positive and are being evaluated for sensitivity to niraparib in vivo. Preliminary data from treated models indicate all models that responded to niraparib treatment had an HRD score above the predetermined cutoff value and included both BRCA mutant and BRCA wild type tumors. Evaluation of niraparib sensitivity across the full set of selected models is ongoing. These initial results indicate that identifying patients with homologous recombination deficiencies using myChoice HRD may help to identify patients who are most likely to respond to treatment with niraparib.

About Niraparib

Niraparib is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor. A Phase 1/2 monotherapy study of niraparib has been completed in more than 100 patients with advanced solid tumors. Two Phase 3 trials are currently ongoing to evaluate a single oral dose of niraparib as a maintenance therapy for patients with ovarian cancer and as a treatment for patients with BRCA-positive breast cancer.

About myChoice HRD™

Myriad's proprietary Homologous Recombination Deficiency (HRD) test detects DNA scars that indicative of a tumor that has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs. High HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in triple-negative breast cancer patients. It is estimated that up to 1.8 million people in the United States and Europe are diagnosed with cancers annually are candidates for treatment with DNA-damaging agents.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com .

Investor/Media Contact:
Jennifer Davis
Sr. Director, Corporate Development & Investor Relations
+1.781.325.1116 or jdavis@tesarobio.com

About Myriad

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Media Contact: Investor Contact:
Ron Rogers Scott Gleason
EVP Corporate Communications VP of Investor Relations
(801) 584-3065 or rrogers@myriad.com          (801) 584-1143 or sgleason@myriad.com

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO or Myriad, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include our expectations regarding future clinical trials with niraparib. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO and Myriad undertake no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of TESARO and Myriad in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2013 and other filings TESARO makes with the Securities and Exchange Commission, and Myriad's Annual Report on Form 10-K for the year ended June 30, 2014 and other filings Myriad makes with the Securities and Exchange Commission.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 0

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 126

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 61

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 95

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 288

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 94

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 153

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Exploring the Trading Landscape for Bitdeer Technologies

Updated Category News Views 99

Whales Are Bullish on Bitdeer Technologies Large investors, often referred to as whales, have shown a strong bullish sentiment towards Bitdeer Technologies. Recent observations from the options trading history reveal a total of eight significant trades in this period. Examining the nature of these trades indicates that approximately 62% were made with optimistic outlooks,...

Continue Reading
Successful Rafi's Amigos Golf Outing Raises Funds for JROTC

Updated Category News Views 188

Successful Fundraising at Rafi's Amigos Golf Outing On a recent day dedicated to supporting local youth, the Rafi's Amigos Golf Outing took place at Beavercreek Golf Club. Despite early rain, the weather brightened, allowing golfers and supporters to enjoy a seamless day on the course. With 116 participants, this year's event was recognized as a remarkable achievement,...

Continue Reading
Trinity Biotech Launches Innovative CGM Technology in India

Updated Category News Views 138

Trinity Biotech Prepares for CGM Launch in India Trinity Biotech plc (NASDAQ:TRIB), based in Dublin, is ready to make a notable stride in diabetes management with the launch of its advanced Continuous Glucose Monitoring (CGM) technology in India. The company has revealed plans for a crucial in-country study aimed at collecting feedback from diabetes patients and...

Continue Reading
Significant Market Growth for Fiberglass Fabrics Expected Soon

Updated Category News Views 259

Fiberglass Fabrics Market Growth Forecast A new market report reveals that the global fiberglass fabrics market is poised for substantial growth, projected to reach an increase of USD 2.83 billion between 2024 and 2028. This impressive expansion is expected to occur at a compound annual growth rate (CAGR) of 7.5% over the forecast period. The driving forces behind this...

Continue Reading
Earnings Insights for Hess Midstream: Key Metrics to Consider

Updated Category News Views 206

Anticipating Hess Midstream's Earnings Results Hess Midstream (NYSE:HESM) is gearing up to release its quarterly earnings report soon, poised to share vital insights that could impact investor sentiment. As the anticipation builds, understanding what to expect is crucial for current and prospective investors alike. Projected Earnings and Market Expectations Analysts are...

Continue Reading